## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `kpv`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/kpv/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/kpv/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/kpv/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/kpv/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/kpv/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/kpv/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `kpv` v58 · content_hash `92332ff9884cfd16…` · thread_head obj-291 · 11 DIVs
- **thesis (c1):** KPV is small enough to be carried straight into the cells that line the gut, and into immune cells, by a transporter called PepT1 - the same doorway the gut normally uses to pull in short fragments of digested protein.
  - c9 [human/active] A 2026 review pulled the KPV work together - how it acts, the reports on inflammation, gut and wound healing, and the safety worries - and stated plainly that n
  - c13 [human/active] A 2012 study worked on the cells lining the airways rather than the gut, and found KPV calmed them through a docking point called MC3R - one of the receptors th
  - c16 [human/active] The Wikipedia entry describes KPV as the three-amino-acid tail end of alpha-MSH, a hormone the body makes itself, and notes that it turns up as an ingredient in
  - c31 [human/active] A 2024 review of peptides and proteins studied for tissue repair lists KPV among them and places it in the wound healing work. It is a survey of what others hav
  - c57 [human/active] A 2025 review of peptide approaches to inflamed bowel disease covers KPV as one of the candidates. It runs no experiment of its own.
  - c68 [human/active] A 2025 paper on peptides and immunity in the retina cites what KPV did in animal models of diabetic eye disease.
  - c69 [human/active] A review covering a decade of KPV work sets out how researchers have tried to formulate it, carry it in tiny particles, and stop it breaking down before it arri
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 1 open · strongest: MATERIAL: Page notes FDA proposed keeping KPV off the compounding list (2026), that the assumed receptor failed three tests, that plain oral → https://miscsubjects.com/api/articles/kpv/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/kpv/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `kpv`
- **title:** KPV: Evidence, Stability, Dosing and the FDA Record
- **url:** https://miscsubjects.com/a/kpv
- **register:** essay
- **updated:** 2026-08-04T20:49:58.543Z
- **tags:** peptide, kpv

## Body

KPV is three amino acids in a row — lysine, proline, valine. It is the tail end of a hormone your own body makes, alpha-MSH, which calms inflammation, darkens skin, and pushes on the heart and blood vessels. Cut the tail off and you keep the calming and lose the other two. That separation is the whole reason anyone works on it.

The evidence state, before anything else on this page. Randomised trials of KPV in people: none. Uncontrolled studies in people: none either. KPV has never been given to a person in any published study, by any route, at any dose. Asking the ClinicalTrials.gov programming interface for it on 4 August 2026 returned a total count of zero, and FDA searched the same databases independently in May 2026 and recorded that it had found no exposure data for products containing KPV given by any route. So the number of people who have ever taken it under measurement is nought, and there is no established human dose, no measured blood level, and no side-effect rate from a study. What does exist is 35 papers. The controlled results in them come from cultured human gut, airway and skin cells, and from mice, rats and rabbits: colitis in mice, a scraped cornea in rabbits, chemotherapy mouth ulcers in rats, a diabetic skin wound in mice. Every controlled win is in a lining one cell thick. Nothing in any species has put KPV against a tendon, a ligament, a joint or a spinal disc. And the counted record of what happens to people who buy it is 35 first-hand reports gathered from public threads, which is a record of exposure and not a test of whether it works.

One disclosure, because it should change how you read the rest. The operator of this site has a commercial interest in compounds described here. That is a reason to weigh what is on this page against the sources it cites rather than against its tone, and every claim below carries the source that supports it for exactly that reason.

Here is what is actually known, in the order it should be read.

Thirty-five papers have KPV in the title or abstract. Every controlled result in all of them came out of a dish, a mouse, a rat or a rabbit. In May 2026 the FDA ran its own search across PubMed, Embase, ClinicalTrials.gov, DailyMed, Drugs@FDA, Micromedex, the European and Japanese pharmacopoeias and the outsourcing-facility reporting database, arrived at the same count, and in July proposed that KPV be kept off the list of substances a pharmacy is allowed to compound. The receptor everyone assumed it works through has been tested three times and it is not the one. Plain KPV swallowed did nothing in the cleanest experiment ever run on it. And the two forms sold under the same name and the same CAS number differ in how much will dissolve by a factor of seven, which is why some people's vials go cloudy and others' do not.

None of that means the compound is inert. It means the honest version of what it does is narrower and stranger than what is being sold, and the parts that are solid are worth knowing exactly.

[[embed:source:w_iydnxytw]]

## What is inflamed, what keeps it inflamed, and what would have to calm down

The tissue at the centre of this compound's whole record is a lining: the single layer of cells covering the inside of your gut, the surface of your eye, your airway, your gums, the underside of your skin. Every controlled win KPV has is in one of those.

**What breaks down.** A lining cell is held to its neighbour by tight junctions. Inflammation loosens them. Once loose, gut contents leak into the wall, immune cells arrive, and the cells release IL-1β, IL-6 and TNF-α — the three signals that show up in every KPV paper. Those signals loosen the junctions further. It is a loop that keeps itself running.

**What makes it break down faster.** More of the same signals. The master switch that turns them on is a protein pair called NF-κB, which sits idle in the body of the cell until inflammation frees it, at which point it walks into the nucleus and switches on the genes for all three cytokines. Every cycle of that loop damages more lining.

**What builds it back.** Lining cells divide fast — the gut resurfaces itself roughly every five days. The layer will rebuild itself if the inflammation stops. That is unusual and it is the reason this class of compound gets attention: you do not need to add anything, you need to remove the thing preventing repair.

**What makes it build back faster, and how strong each link is.** KPV walks into the nucleus itself and physically blocks NF-κB's ride into the nucleus — shown in a human airway cell line with the binding site identified, strong for a dish. That drops IL-1β, IL-6 and TNF-α — shown in mouse gut, rat gum, rabbit eye, human skin cells, consistent across four tissues, strong. Lower cytokines let the lining reseal — shown in mice and rats by wound closure and colon length, moderate. The same happens in a person — never tested by anyone, in any published study, by any route.

That last line is a row in the table, not the story. What follows is everything above it.

## The tanning half was cut off and the calming half stayed

Alpha-MSH is thirteen residues — SYSMEHFRWGKPV. The last three are K, P and V. KPV as a free base is C16H30N4O4, molecular weight 342.43 g/mol, CAS 67727-97-3. The acetate salt adds an acetic acid molecule for 402.5 g/mol and carries the same CAS number in most references. Neither form has a UNII code, a United States Pharmacopeia monograph, a European Pharmacopoeia monograph or a Japanese Pharmacopoeia monograph.

Alpha-MSH itself was studied as an anti-inflammatory for decades and never became one, because it drives melanin production and nobody wanted to tan a colitis patient to treat their colon. Cutting the molecule down to its last three residues removed that problem: KPV keeps almost all of the anti-inflammatory capacity of the full hormone and produces no pigment change at all.

[[embed:source:w_iz1zla8v]]

That is the design idea, stated by the people who proposed it, and it is the one claim about KPV that the literature and the regulator both accept without argument.

## The obvious receptor was checked three times and it is not the one

Alpha-MSH works by docking onto melanocortin receptors, MC1 through MC5. The obvious guess was that its three-residue tail docks onto the same ones, more selectively. Three separate lines of evidence say it does not.

KPV cannot push radiolabelled alpha-MSH off rat brain tissue, off mouse melanoma cells, or off mouse immune cells carrying MC1R. Unlike alpha-MSH, it raises no cyclic AMP in those cells — meaning the docking signal never fires. Drug-blocking and gene-knockout approaches both failed to pin KPV's anti-inflammatory and wound-healing effects on MC2, MC3 or MC4.

[[embed:source:w_4lw9q2jv]]

Human skin cells read the same. Neither alpha-MSH nor KPV produced any rise in cyclic AMP in HaCaT cells or in ordinary human skin cells. What did move was calcium inside the cell, across concentrations from 10⁻¹⁵ to 10⁻⁷ M.

[[embed:source:w_udmw8780]]

The structural argument is blunter. KPV does not contain the sequence a molecule needs in order to bind any known melanocortin receptor at all — and it keeps the activity anyway. What it uses instead is not known.

[[embed:source:w_wo06gy2y]]

So two things are settled. The anti-inflammatory effect is real in cells and animals. It is not a melanocortin receptor effect. What is open is what it is instead — and note the shape of that: this is a negative answer to a specific question, not an unexplored area. People were looking, and they found out it was not that.

## It stops the inflammation switch from reaching the nucleus

The best-worked-out candidate is physical interference. KPV gets in the way of the ride NF-κB takes into the nucleus.

In an immortalised human airway lining cell line, KPV cut NF-κB reporter activity, matrix metalloproteinase-9 activity, and release of IL-8 and eotaxin, and it did more of all of that at higher doses. The effect tracked with KPV's own movement into the nucleus, with stabilisation of IκBα, and with tagged p65RelA failing to get into the nucleus. Competition experiments put KPV at the importin-α3 binding site on p65RelA — importin-α3 is the shuttle protein that carries NF-κB in — probably jamming armadillo domains 7 and 8. A comparison peptide, γ-MSH, needed MC3R in the same experiment. KPV did not.

[[embed:source:w_0k5anu21]]

Downstream, the pattern is the same everywhere it has been looked at: IL-1β, IL-6 and TNF-α fall. In immune cells stimulated with bacterial wall fragments, in colon tissue from mice with colitis, in rat gum tissue and in human skin cells stressed with air pollution particles, those three are what move.

[[embed:source:w_tfx8zspw]]

Calming inflammation in a dish is not the same as calming inflammation in a person, and the gap between those two is where every unanswered question about KPV lives.

## A door in the gut wall that opens wider the sicker the gut gets

PepT1 is a transporter built to pull two- and three-amino-acid fragments out of the gut and into the cell. It sits in the small intestine normally, is barely present in a healthy colon, and appears in large amounts in the colon lining during inflammatory bowel disease. KPV is a tripeptide. It fits through.

Radiolabelled KPV is carried by human PepT1 with a half-saturation point of roughly 160 µM in Caco2-BBE gut lining cells and roughly 700 µM in Jurkat immune cells, and unlabelled KPV competes with glycyl-sarcosine, the standard test substrate for that transporter. Once inside, concentrations in the billionths of a molar were enough to shut down NF-κB and MAP kinase signalling.

[[embed:source:w_ky34gd73]]

The transporter is not incidental to the story — it is the story. In mice given azoxymethane plus dextran sodium sulfate to trigger colitis and then colon cancer, KPV prevented the cancer in normal animals and did nothing whatsoever in animals bred without PepT1. Take the door away and the drug stops working.

[[embed:source:w_txhlsxnq]]

This is why swallowing and rectal use get discussed at all for a peptide you would otherwise assume needs a needle. It also makes a specific, testable prediction: the sicker the colon, the more doors, and therefore the more gets in. That prediction has been confirmed in mice. It has never been checked in a person.

## Every controlled result comes from a dish, a mouse, a rat or a rabbit

The three tables below are the complete usable evidence base, split by what kind of system produced each result. Doses are exactly as the papers report them.

**In a dish**

| Study | Model | Route | Dose | What happened |
|---|---|---|---|---|
| Dalmasso 2008 (PMID 18061177) | Caco2-BBE, HT29-Cl.19A, Jurkat T cells | in the culture fluid | billionths of a molar; half-saturation 160 µM in gut cells, 700 µM in Jurkat | NF-κB and MAP kinase signalling shut down; uptake through PepT1 confirmed with tritium-labelled KPV |
| Land 2012 (PMID 22837805) | 16HBE14o- human airway lining | in the culture fluid | more effect at higher dose | IL-8, eotaxin, MMP-9 down; p65RelA blocked from the nucleus at the importin-α3 site |
| Cutuli 2000 (PMID 10670585) | *Staphylococcus aureus*, *Candida albicans* | in the culture fluid | trillionths of a molar and above | Colonies failed to form; yeast survival and germ-tube formation fell; white cells killed both organisms better rather than worse |
| Grieco 2005 (PMID 15946192) | Azole-resistant *Candida* species | in the culture fluid | not stated | The [Ac-CKPV]₂ double version kills the yeast; NMR shows a stretched backbone with a β-turn |
| Hedley 2004 (PMID 15102092) | HaCaT and ordinary human skin cells | in the culture fluid | 10⁻¹⁵ to 10⁻⁷ M | No cyclic AMP rise; calcium inside the cell rose |
| Pawar 2017 (PMID 28343991) | Sliced human cadaver skin | on the surface | left on, against microneedles, against a small electric current | Left on its own, nothing crossed above the 0.01 µg/mL detection limit; microneedles gave 4.4 µg/cm²/h; adding current multiplied that by 35 |
| Tissue Cell 2025 (PMID 40073467) | HaCaT skin cells and a 3D skin model, air pollution insult | in the culture fluid | 50 µg/mL | Cells survived; IL-1β, reactive oxygen and caspase-1 activation all fell |
| Cytotechnology 2026 (PMID 42064835) | HepG2 liver cells, fat-loaded | in the culture fluid | 100 µg/mL | Fat accumulation and fatty-acid synthase suppressed through PPARγ, with no cell death |

**In animals**

| Study | Model and species | Route | Dose | What happened |
|---|---|---|---|---|
| Lipton 1984 (PMID 6333677) | Rabbit fever from white-cell pyrogen | into the brain and into the body | 0.5–2.0 mg into the brain; 2–200 mg into the body | Fever fell by both routes; weaker than whole alpha-MSH |
| Hiltz & Lipton 1989 (PMID 2550304) | Mouse ear swelling, picryl chloride | into the body | graded doses | Swelling fell, more at higher doses, compared against a large steroid dose |
| Bonfiglio 2006 (PMID 16965771) | Rabbit corneal scrape | eye drops | 1, 5 or 10 mg/mL, 30 µL, two drops four times a day for 4 days | 8 of 8 corneas fully resurfaced by 60 hours; the effect disappeared when nitric oxide production was blocked |
| Dalmasso 2008 (PMID 18061177) | Mouse DSS and TNBS colitis | in the drinking water | 100 µM | Weight loss, myeloperoxidase and inflammatory cytokine messenger RNA all reduced |
| Kannengiesser 2008 (PMID 18092346) | Mouse DSS colitis and CD45RB-high transfer colitis | into the body | not stated in abstract | Earlier recovery, weight regained, less immune cell infiltrate and less myeloperoxidase; in mice with a broken MC1R, every treated animal survived |
| Laroui 2010 (PMID 19909746) | Mouse DSS colitis | swallowed, 400 nm particles in an alginate–chitosan gel | 12,000 times lower than free solution | The same protection at one twelve-thousandth of the concentration |
| Viennois 2016 (PMID 27458604) | AOM/DSS colitis-driven cancer, normal against PepT1-knockout mice | swallowed | not stated in abstract | Cancer prevented in normal mice; no effect at all without PepT1 |
| Xiao 2017 (PMID 28143741) | Mouse ulcerative colitis | swallowed, hyaluronic-acid particles in a chitosan/alginate gel | ~272 nm particles | Lining healed faster and TNF-α fell; better than plain KPV particles |
| ACS Biomater Sci Eng 2021 (PMID 34547895) | Rat TNBS ulcerative colitis | rectal, thiolated γ-polyglutamic acid gel | 4% polymer gel | Disease activity, colon shortening, myeloperoxidase, TNF-α and IL-6 all reduced; plain rectal KPV fell apart too fast to work |
| Biomater Sci 2021 (PMID 34846053) | Rat chemotherapy mouth ulcers, MRSA-infected | sticky gel that sets at body heat | 2% EGCG carrier | Gum ulcers repaired, IL-1β and TNF-α down, IL-10 up, and it killed *S. aureus* |
| Int J Biol Macromol 2022 (PMID 36240893) | Diabetic mouse full-thickness wound | layered film dressing | KPV released over 3 days, EGF released in response to glucose | Faster closure, through less inflammation, new blood vessel growth and collagen laid down |
| Adv Healthc Mater 2024 (PMID 39252648) | Mouse blood vessel calcification | KPV–rapamycin particles with no carrier | self-assembling | Calcification blocked; inflammation down and cell self-cleaning switched on |
| Sci Adv 2026 (PMC12802832) | Mouse DSS colitis and acute lung injury | swallowed, self-uncaging prodrug | proKPV 0.5 and 2.5 mg/kg daily × 7 days | Weight, disease activity and colon length all protected — while **plain KPV at the matching 1 mg/kg peptide dose did nothing at all** |

**In people**

| Study | Model | Route | Dose | What happened |
|---|---|---|---|---|
| — | — | — | — | Nothing published. KPV has never been given to a person in a published study, by any route |

Asking the ClinicalTrials.gov programming interface for KPV peptide on 4 August 2026 returned `{"totalCount": 0}`.

[[embed:source:w_46rh3j3w]]

FDA searched independently and found the same. The nomination that put KPV in front of the agency cited nine references: eight were animal studies of various alpha-MSH derivatives, and the ninth was a skin-permeation experiment on cadaver skin.

[[embed:source:w_4lw9q2jv]]

## Plain KPV falls apart, which is why most of the research is about packaging

Read the animal table again and one thing is impossible to miss: hydrogels, nanoparticles, liposomes, film dressings, prodrugs, gels that set at body heat. That is not fashion. That is a whole field routing around a defect.

Put KPV under acid, alkali or hydrogen peroxide and the main thing you get back is lysine-proline-diketopiperazine. The lysine and proline ends curl round and bond to each other, the ring closes, and the peptide is gone.

[[embed:source:w_4hqievsz]]

KPV solution given rectally was described flatly as "very unstable", which is why the rat colitis work needed a thiolated polymer gel just to hold it together for two hours at body temperature.

[[embed:source:w_6tepv8p6]]

The 2026 prodrug paper is the cleanest measurement of what that costs. Plain KPV swallowed at 1 mg/kg did nothing in mouse colitis. The same peptide, chemically caged so it survives the stomach and uncages only where reactive oxygen marks inflamed tissue, worked at half that dose and reached 3.8 times the concentration in the colon.

[[embed:source:w_yd7rqb37]]

Trying to toughen the molecule by chemistry rather than packaging has cost the activity outright. Sticking a sugar-alkyl group on the lysine produced versions that shrugged off protein-cutting enzymes and killed nothing under any condition tested — including the acetylated parent.

[[embed:source:w_ggr3cicc]]

Two things follow, and both are practical.

Nothing in the animal record shows that plain, unpackaged KPV swallowed reaches inflamed tissue in a useful amount. One paper specifically shows it does not.

And the storage numbers in the regulatory file are the ones to work from: dry powder is reported good for up to three years at −20 °C, two years at 4 °C, and three months at 15 °C, while once it is in water it is reported at six months at −80 °C, one month at −2 °C and one week at 10 °C.

[[embed:source:w_4lw9q2jv]]

## The two salts differ in how much will dissolve by a factor of seven

This is the detail most likely to leave you holding a cloudy vial and wondering whether you ruined it.

KPV free base dissolves in water only up to 0.70 mg/mL. KPV acetate is reported to dissolve at 5 mg/mL.

[[embed:source:w_4lw9q2jv]]

Now do the arithmetic everyone does. A 10 mg vial with 2 mL of water in it is aiming for 5 mg/mL.

If the powder is the acetate salt, 5 mg/mL sits exactly on the reported ceiling — it will go in, with nothing to spare.

If the powder is the free base, 5 mg/mL is about seven times more than will dissolve. It physically cannot all go into solution. What you get is a suspension that looks nearly right, and the amount of actual peptide in each syringe depends on how recently you swirled it.

The part that makes this a real problem rather than a solvable one: the two forms share the same CAS number and are labelled inconsistently, so the container often does not tell you which one you have. FDA said exactly that, and called the naming conventions non-compliant with INN, IUPAC and USAN standards for that reason. If you want a fill that works either way, 0.70 mg/mL is the number that clears both — a 10 mg vial in 14 mL, which nobody does, or a smaller vial in more water.

## One mark on the syringe is fifty micrograms

A U-100 insulin syringe holds 1 mL across 100 marks. One mark is 0.01 mL. Everything else falls out of the concentration.

Start there:

- 10 mg powder ÷ 2 mL bacteriostatic water = **5 mg/mL = 5,000 mcg/mL**
- 1 mark = 0.01 mL × 5,000 mcg/mL = **50 mcg per mark**

| Marks on the barrel | Volume | Dose at 5 mg/mL | Dose at 2.5 mg/mL (10 mg in 4 mL) | Dose at 2 mg/mL (10 mg in 5 mL) |
|---|---|---|---|---|
| 2 | 0.02 mL | 100 mcg | 50 mcg | 40 mcg |
| 4 | 0.04 mL | 200 mcg | 100 mcg | 80 mcg |
| 5 | 0.05 mL | 250 mcg | 125 mcg | 100 mcg |
| 10 | 0.10 mL | 500 mcg | 250 mcg | 200 mcg |
| 20 | 0.20 mL | 1,000 mcg (1 mg) | 500 mcg | 400 mcg |
| 40 | 0.40 mL | 2,000 mcg (2 mg) | 1,000 mcg | 800 mcg |

Putting the same 10 mg into 4 mL instead of 2 mL halves every number in the column and doubles the volume you inject for a given dose. That is usually the point: small doses are easier to measure when each mark is worth less. It also drops you to 2.5 mg/mL, which is under the acetate ceiling with room to spare and still five times over the free base's, so it does not solve the salt problem.

The dose people actually take rests on a unit conversion, not a trial. Scaled from rodent studies by body surface area, a human-equivalent starting dose has been published at around 0.2 mg — four marks on a 5 mg/mL fill.

[[embed:source:s7]]

That number carries the weight of an arithmetic conversion and nothing else. Nobody has measured how the body absorbs and clears KPV free base or KPV acetate, in any species. There is no measured half-life, no figure for how much reaches the blood, and no dose-response curve anywhere that would let a human dose be worked out rather than scaled from a mouse.

[[embed:source:w_4lw9q2jv]]

## What people taking it report, counted: 28 helped, 4 worse, 3 both, of 35

Sixty first-hand posts about KPV are catalogued as sources on this page — fifty from Reddit, ten from X, all pulled on 29 June 2026. Twenty-five of them are guides, product write-ups, questions, or regulatory commentary with no outcome in them. That leaves **35 posts where a named person says what they took and what happened**.

Sorted by what they actually reported:

| What was reported | Posts | Share of the 35 |
|---|---|---|
| Something got better | 28 | 80% |
| Something got better *and* a bad reaction happened, or the route mattered | 3 | 9% |
| A bad effect was the whole report | 4 | 11% |
| Nothing at all happened | 0 | 0% |

Read that honestly in both directions. This is a curated set, pulled from threads people started because they had something to say, and the direction of that bias is upward — nobody posts "took a peptide, nothing occurred, no further questions." The zero in the bottom row is the tell. For DSIP, catalogued the same way on the same day, five of thirty-five reports said nothing happened. Here, none did. Either KPV does something noticeable to nearly everyone who takes it, or the silent non-responders are not in the sample. Both of those can be true at once.

What the set is genuinely good for is a dose survey and a side-effect list, and on those two it is consistent. On a 10 mg vial in 2 mL — 50 mcg per mark — the reported range runs from four marks to ten. **200 to 500 mcg a day under the skin is what people take.**

### The 28 who said something got better

Twelve days under the skin at 200 mcg, one 5 mg vial, for gut symptoms — labelled anecdotal:

[[embed:source:s17]]

Forty days at 500 mcg a day, for mast cell symptoms:

[[embed:source:s20]]

Same condition, a different person, putting a number on it:

[[embed:source:s24]]

r/MCAS again, on fatigue and food tolerance:

[[embed:source:s23]]

Roughly 300 mcg a night by injection, from r/MCAS — and, from the same thread, the swallowed form causing flares where the injected form did not:

[[embed:source:s47]]

Skin is the second cluster. Eczema, four to five weeks in, with symptoms returning within two days of stopping:

[[embed:source:s60]]

[[embed:source:s75]]

[[embed:source:s58]]

Hidradenitis, in a stack:

[[embed:source:s100]]

Then the reports where the benefit is real but short. Two people independently describe roughly forty-eight hours of relief per injection and then a return to baseline:

[[embed:source:s61]]

[[embed:source:s53]]

And the outliers, which are worth keeping visible precisely because a single report proves nothing: a person whose supraventricular tachycardia episodes stopped for two months and came back two days after stopping the peptide:

[[embed:source:s83]]

[[embed:source:s82]]

[[embed:source:s62]]

The rest of the 28 — histamine tolerance, general inflammation, skin, nail fungus, dandruff, food reactions, rheumatoid arthritis alongside prescribed drugs, sacroiliac pain in a stack, hair thickening in a blend, and several "keeps it in the stack year-round" posts:

[[embed:source:s22]]

[[embed:source:s27]]

[[embed:source:s32]]

[[embed:source:s48]]

[[embed:source:s63]]

[[embed:source:s64]]

[[embed:source:s74]]

[[embed:source:s85]]

[[embed:source:s89]]

[[embed:source:s103]]

### The 4 where a bad effect was the whole report

At the same doses. This matters — the negatives are not from people megadosing.

200 mcg, and the complaint is not physical at all:

[[embed:source:s25]]

250 mcg a night, day four:

[[embed:source:s46]]

An acute reaction within an hour of a small injected volume:

[[embed:source:s43]]

Dizziness, broken sleep, headaches, brain fog and fatigue, from a long-covid gut thread:

[[embed:source:s19]]

### The 3 who got both

Eight days of clear improvement, then red bumps out of nowhere:

[[embed:source:s54]]

Gut repair, but only after months of climbing the dose slowly, with paradoxical reactions early:

[[embed:source:s21]]

And the one that splits by route rather than by person — swallowed did nothing measurable, injected moved a blood marker a long way:

[[embed:source:s101]]

### Two patterns worth naming out loud

The first is a frame, not a finding. Fatigue, apathy and flu-like malaise appear over and over at 200–500 mcg, and the standard community explanation is a die-off or healing flare. That explanation cannot be wrong, because there is no result it excludes — every bad reaction becomes evidence the compound is working. Treat it as what it is: an unfalsifiable story wrapped around an adverse effect.

The second is a real, testable claim, and it appears in enough reports to take seriously: people who started very low and climbed slowly report the paradoxical reactions going away. That is a dose-response observation, and it is the only actionable thing the whole self-report record produces.

[[embed:source:s21]]

Duration is the other thing the reports agree on and the animal literature never measured. The effect is described as lasting days, not weeks — which fits a three-amino-acid peptide with no measured half-life and a known tendency to curl up into a diketopiperazine and stop existing.

[[embed:source:s53]]

None of this substitutes for a trial. It does establish three facts you would otherwise learn by accident: the dose is 200–500 mcg under the skin, bad reactions at that dose are common enough to fill threads, and the swallowed and injected forms are not experienced as the same thing.

## Swallowed, injected, rubbed on, sprayed up the nose — what changes

All four are sold. The evidence behind each is not remotely equal.

**Swallowed** has the strongest mechanical case, because PepT1 is a real door, KPV is a real fit for it, and the door opens wider in inflamed bowel. Against that: the single experiment that pitted plain swallowed KPV against a packaged version found the plain version inert.

**Rectal** puts the peptide against the target tissue directly, and was shown to need a stabilising gel to survive long enough to do anything.

**Rubbed on** has an explicit measurement against it. Across human cadaver skin, KPV left on the surface crossed at a rate below the 0.01 µg/mL detection limit. It took microneedles punching through the outer layer to reach 4.4 µg/cm²/h, and a small electric current on top of that to multiply it further. Nothing crosses intact skin on its own in any amount you can measure.

[[embed:source:w_62ka3qz2]]

FDA reached the same conclusion and pointed out that it cuts both ways: poor skin crossing limits how much reaches the bloodstream and therefore limits systemic toxicity, and it equally limits KPV's usefulness as a cream, because it may never reach the living skin layers under the dead outer one.

[[embed:source:w_4lw9q2jv]]

**Sprayed up the nose** has no published measurement of any kind.

## It kills bacteria and yeast in a dish and has never been measured in a body

Alpha-MSH peptides including KPV stopped *Staphylococcus aureus* forming colonies and cut *Candida albicans* survival and germ-tube formation, down to concentrations in the trillionths of a molar. Unusually for an anti-inflammatory, they made white blood cells kill both organisms better rather than worse — most things that calm inflammation blunt that.

[[embed:source:w_8b4pdcfy]]

The version taken furthest toward antifungal development is the double, [Ac-CKPV]₂, built by joining two KPV units through a cysteine-cysteine bridge. It works against *Candida* strains that azole drugs no longer touch.

[[embed:source:w_4rk4kjx2]]

The MRSA result in the rat mouth-ulcer model is the closest thing to a confirmation in a living animal, and it needed a sticky gel holding the peptide against the wound for seven hours to get there.

[[embed:source:w_jcn0rn64]]

## Where the evidence stops, and the swap that gets made

Two things in this file are solid enough to act on, and neither is a musculoskeletal finding.

The first is inflammation in a lining. Every controlled win KPV has is in one — bowel, cornea, airway, skin, gum. If your problem is a gut that is inflamed, that is the strongest part of this record and it is genuinely the strongest part.

The second is the pairing with BPC-157, which is what most gut protocols actually run.

[[embed:bpc-kpv-gut-repair]]

Now the swap, because it is made constantly and it is worth being able to spot.

No study in any table above used a tendon, a ligament, a disc or a joint. There is no rat Achilles study. No ligament cut study. No cartilage study. The wound-healing results are all in linings — a scraped cornea, a diabetic skin wound, a mouth ulcer — and resealing a one-cell-thick lining is a different job from rebuilding collagen in a tendon. Lining cells divide every few days and re-cover a surface. Tendon rebuilds by laying down and remodelling collagen fibres over months, using different cells and a different signal set.

So the sentence "KPV helps tissue heal" is true and useless, and it is the sentence that does the work. Someone reads it and hears "KPV will help my rotator cuff." That is a cornea result laundered into a shoulder claim, and the laundering happens in the word *tissue*.

The honest version is four clauses long. KPV reduces inflammatory signalling in the linings of animals. It has never been given to a person in a published study. It has no measured human dose. And it is currently proposed for exclusion from legal compounding in the United States.

## FDA proposed in July 2026 that KPV stay off the compounding list

The regulatory position has two layers and they get conflated constantly.

The older layer: KPV sits on FDA's table of bulk drug substances that were nominated for compounding and then withdrawn by whoever nominated them, filed under substances that may present significant safety risks. The agency's entry says it "has not identified any human exposure data on drug products containing KPV administered via any route of administration" and "lacks important information regarding any safety issues raised by KPV, including whether it would cause harm if administered to humans."

[[embed:source:w_fquamfa9]]

The newer layer matters more. The nomination was withdrawn, and FDA chose to take KPV to its advisory committee anyway. On 23 July 2026 the Pharmacy Compounding Advisory Committee heard KPV free base and KPV acetate alongside BPC-157, TB-500 and MOTS-c, with the uses under evaluation recorded as wound healing and inflammatory conditions.

[[embed:source:w_x3r14ud2]]

FDA's position going in was not ambiguous: "FDA is proposing that KPV (free base) NOT be included on the 503A Bulks List" and "FDA is proposing that KPV acetate NOT be included on the 503A Bulks List."

[[embed:source:w_b5ztk84s]]

The reasoning, dated 12 May 2026, weighed four criteria and found against on all four.

Neither form is well characterised: the naming is inconsistent, and no certificate of analysis, impurity profile, clumping test or microbiology data was supplied or found in the literature.

How much it has historically been compounded is unknown: outsourcing facilities reported compounding no KPV products at all between January 2017 and June 2025, while telehealth and compounding websites sell injectable, swallowed, topical and nasal-spray KPV for inflammatory conditions, wound healing, skin health, gut health, killing microbes, and protection against nerve damage and stroke.

There is no evidence it works, because there is no human data.

And there is no safety evidence in either direction.

[[embed:source:w_4lw9q2jv]]

What that means in practice: getting onto the 503A Bulks List is what makes a substance lawfully compoundable when it has no monograph and is not part of an approved drug. FDA has proposed it not get on.

## Unknown is not the same as safe

FDA's Office of Surveillance and Epidemiology searched the FDA Adverse Event Reporting System and the medical literature for harms linked to KPV, through 3 December 2025. The reporting system returned nothing. The literature search found no cases. A separate search of the Human Foods Program adverse event system covering 1 January 2004 to 3 December 2025 also came back empty.

[[embed:source:w_4lw9q2jv]]

An empty harm database for a substance nobody has published on giving to humans measures the literature, not the compound. Reporting to that system is voluntary, and compounders working under section 503A generally do not report to FDA at all. Meanwhile four of the thirty-five first-hand posts above describe a bad reaction, and none of those four is in any database.

No acute toxicity study exists. No repeat-dose toxicity study. No genotoxicity study. No developmental or reproductive toxicity study, of either form. FDA's stated worry is clumping and whether the immune system reacts to it, and neither can be assessed without the impurity and aggregate data the nomination never supplied.

The narrower operative fact: what circulates is research-grade powder from suppliers whose certificates of analysis FDA could not locate, and the agency's specific objection is that nobody can tell from the label whether a given vial holds the free base or the acetate — which, per the section above, decides whether your 10 mg in 2 mL is a solution or a suspension.

## Where every number above came from

**Primary literature, by PubMed identifier.** PMID 18061177 (PepT1 uptake, *Gastroenterology* 2008); PMID 18092346 (DSS and transfer colitis, *Inflammatory Bowel Diseases* 2008); PMID 27458604 (PepT1 knockout and colitis-driven cancer, 2016); PMID 22837805 (p65RelA blocked from the nucleus, 2012); PMID 21222263 and PMID 18612139 (the melanocortin-receptor-independence argument); PMID 15102092 (skin cell cyclic AMP and calcium); PMID 10670585 and PMID 15946192 (killing microbes, and the CKPV double); PMID 16965771 (rabbit cornea); PMID 2550304 and PMID 6333677 (the original mouse and rabbit work, 1989 and 1984); PMID 25298219 (the stability assay and the diketopiperazine breakdown product); PMID 28343991 (human cadaver skin); PMID 19909746, PMID 28143741, PMID 34547895, PMID 34846053, PMID 36240893, PMID 39252648 and PMC12802832 (the packaging literature); PMID 29953505 (sugar-alkyl versions, activity lost); PMID 40073467 and PMID 42064835 (recent skin and liver cell work).

**Trial registries.** ClinicalTrials.gov programming interface v2, query "KPV peptide", 4 August 2026: `{"totalCount": 0}`. No registered study of KPV in people exists.

[[embed:source:w_46rh3j3w]]

**Regulatory record.** FDA's evaluation of KPV-related bulk drug substances dated 12 May 2026; the briefing document proposing exclusion from the 503A Bulks List; the Federal Register notice of 16 April 2026 announcing the meeting and the uses evaluated; and the standing FDA page listing KPV among bulk substances nominated but withdrawn.

[[embed:source:w_zjkqhidi]]

**Chemistry.** PubChem CID 125672 for the free base; CAS 67727-97-3 for both forms; molecular weight 342.43 g/mol free base and 402.5 g/mol acetate; water solubility 0.70 mg/mL free base and 5 mg/mL acetate.

**Both sides on the record.** In favour, the researchers who characterised the molecule: Brzoska and colleagues concluded that keeping the anti-inflammatory effect while losing the pigment effect makes KPV "an alternative for antiinflammatory therapy", and that its physical properties and low expected production cost suit inflammatory skin and bowel disease. Böhm and Luger, cited in FDA's own nonclinical review, went further and called for clinical studies to find out whether KPV could heal skin wounds and ulcers — a call that, as of August 2026, nobody has answered. Against, the regulator, in its own words: "There is a lack of clinical and nonclinical safety information on the use of KPV (free base) and KPV acetate. FDA is particularly concerned about the lack of any human data on drug products containing these substances…"

[[embed:source:w_4lw9q2jv]]

**The three hardest numbers in the file**, because everything else is softer than they are: nothing measurable crosses intact human skin, at a detection limit of 0.01 µg/mL; the PepT1 half-saturation point in gut lining is 160 µM; and the main breakdown product under stress is lysine-proline-diketopiperazine.

*KPV is not an approved drug in any country. Nothing here is a dosing or treatment recommendation.*

The sibling objects for this page, each one inspectable on its own terms:

[[embed:bpc-157]]

[[embed:tb-500]]

[[embed:thymosin-alpha-1]]

[[embed:ghk-cu]]

[[embed:ara-290]]


## Claims (48 of 133 ranked)

- **c110** [mechanistic w=0.3] The hash chain on this page proves a source has not been altered since it was recorded. It says nothing about whether the source is true.
  - who_claims: miscsubjects protocol
  - slot: limitations
- **c334** [mechanistic w=0.3] The KPV evidence gathered here is mostly animal work and personal accounts. What exists from people is thin.
  - who_claims: miscsubjects protocol
  - slot: limitations
- **c335** [mechanistic w=0.3] No dose, no protocol and no course of care is recommended anywhere on this page. It is a catalogue of what has been reported.
  - who_claims: miscsubjects protocol
  - slot: limitations
- **c9** [human w=0.8] A 2026 review pulled the KPV work together - how it acts, the reports on inflammation, gut and wound healing, and the safety worries - and stated plainly that no trials in people have been completed.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s7
- **c13** [human w=0.8] A 2012 study worked on the cells lining the airways rather than the gut, and found KPV calmed them through a docking point called MC3R - one of the receptors the body's own anti-inflammatory hormone uses.
  - who_claims: grok/grok-4.3
  - slot: mechanism
  - sources: s11
- **c57** [human w=0.8] A 2025 review of peptide approaches to inflamed bowel disease covers KPV as one of the candidates. It runs no experiment of its own.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s55
- **c7** [human w=0.65] Nothing on this KPV page is medical advice. It is a catalogue of what has been reported, sorted by how strong the evidence behind each report is. Decisions about your own health belong with a qualified doctor who knows your history.
  - who_claims: system/protocol
  - slot: disclaimer
- **c2** [preclinical w=0.5] In mice given colitis with two standard chemical triggers, DSS and TNBS, KPV swallowed by mouth left the bowel wall visibly less inflamed when the tissue was examined under a microscope.
  - who_claims: system/unknown
  - slot: what_is_known
  - sources: s2, s3
- **c14** [preclinical w=0.5] A 2016 mouse study reported that KPV, carried in through the PepT1 doorway, cut the number of bowel tumours that normally follow long-running colitis in these animals.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s12
- **c15** [preclinical w=0.5] In 2017 researchers coated tiny carrier particles with hyaluronic acid so they would stick to inflamed bowel, loaded them with KPV, and tested them in mice with ulcerative colitis.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s13
- **c79** [preclinical w=0.5] The 2008 paper that put KPV on the map showed the same thing twice over: gut cells in a dish and mice with colitis both produced fewer inflammatory signalling molecules once KPV had been carried in through PepT1.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s77
- **c301** [preclinical w=0.5] In that same mouse colitis work the animals given KPV scored lower on the overall disease activity index, the combined score of weight loss, stool consistency and bleeding.
  - who_claims: system/unknown
  - slot: what_is_known
  - sources: s2, s3
- **c302** [preclinical w=0.5] Gut tissue from those KPV-fed mice was producing less of the inflammatory signalling molecules that drive the damage in colitis.
  - who_claims: system/unknown
  - slot: what_is_known
  - sources: s2, s3
- **c86** [mechanistic w=0.4] The disclaimer on this page carries no source and does not need one. It states a limit on what the page is, rather than a fact about KPV that could be checked against a study.
  - who_claims: kimi/moonshot-v1-8k (adversary)
- **c109** [runtime w=0.35] KPV is a peptide three amino acids long - lysine, proline, valine - and this page is where it is catalogued: every claim about it sorted by how strong the evidence behind it is, and tied to its source by a hash chain.
  - who_claims: miscsubjects protocol
  - slot: what_it_is
- **c333** [runtime w=0.35] This page records what the published literature and the internet say about KPV. It is not a set of clinical recommendations.
  - who_claims: miscsubjects protocol
  - slot: what_it_is
- **c8** [mechanistic w=0.3] A 2017 study tested whether KPV could be pushed through intact skin, with inflamed skin as the target. It is an experiment in delivery, and it reports nothing about outcomes in people.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s6
- **c10** [mechanistic w=0.3] A 2026 paper described a new way of packaging KPV and similar peptides so they survive being swallowed, aimed at inflamed bowel conditions.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s8
- **c92** [anecdotal w=0.3] An X post describes KPV as giving the anti-inflammatory part of alpha-MSH without the rest of what that hormone does.
  - who_claims: grok-4.3
  - slot: who_claims_what
  - sources: s87
- **c96** [anecdotal w=0.3] An X post in Italian promotes KPV for IBS, for pouches in the bowel wall and for gut inflammation, and claims it beat cortisone in animal studies. The post cites nothing for that comparison.
  - who_claims: grok-4.3
  - slot: who_claims_what
  - sources: s91
- **c97** [anecdotal w=0.3] An X post describes KPV as a gut anti-inflammatory the writer takes in their own stack and finds easy to tolerate.
  - who_claims: grok-4.3
  - slot: who_claims_what
  - sources: s92
- **c98** [anecdotal w=0.3] An X post recommends KPV on the grounds that several people the writer knows were helped with bowel problems, Crohn's disease and IBS among them.
  - who_claims: grok-4.3
  - slot: who_claims_what
  - sources: s93
- **c103** [anecdotal w=0.3] An X post mentions the writer's own continuing use of KPV inside a stack and reports it as going well, without giving any detail.
  - who_claims: grok-4.3
  - slot: who_claims_what
  - sources: s98
- **c16** [human w=0.8] The Wikipedia entry describes KPV as the three-amino-acid tail end of alpha-MSH, a hormone the body makes itself, and notes that it turns up as an ingredient in skincare products.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s14
- **c31** [human w=0.8] A 2024 review of peptides and proteins studied for tissue repair lists KPV among them and places it in the wound healing work. It is a survey of what others have done and adds no new data.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s29
- **c68** [human w=0.8] A 2025 paper on peptides and immunity in the retina cites what KPV did in animal models of diabetic eye disease.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s66
- **c69** [human w=0.8] A review covering a decade of KPV work sets out how researchers have tried to formulate it, carry it in tiny particles, and stop it breaking down before it arrives.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s67
- **c1** [preclinical w=0.22] KPV is small enough to be carried straight into the cells that line the gut, and into immune cells, by a transporter called PepT1 - the same doorway the gut normally uses to pull in short fragments of digested protein.
  - who_claims: system/unknown
  - slot: mechanism
  - sources: s1
- **c67** [preclinical w=0.22] A 2025 review of anti-inflammatory peptides in animal models of inflamed bowel disease singles KPV out among the colitis candidates. It surveys animal work and reports nothing from people.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s65
- **c300** [preclinical w=0.22] Once KPV is inside the cell it damps down two of the switches that turn inflammation on: NF-κB, the master switch for inflammatory genes, and the MAP kinase relay that feeds into it.
  - who_claims: system/unknown
  - slot: mechanism
  - sources: s1
- **c30** [mechanistic w=0.3] A 2024 study built particles out of KPV and rapamycin that hold themselves together with no carrier material at all, aimed at calcium build-up in the walls of blood vessels.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s28
- **c42** [mechanistic w=0.3] A 2018 paper recorded the central problem with KPV: the plain molecule breaks down quickly once it is in the body.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s40
- **c80** [mechanistic w=0.3] A 2024 abstract lists the KPV tripeptide as one ingredient in a temperature-sensitive gel, built to hold what it carries until body heat releases it.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s78
- **c309** [mechanistic w=0.3] Those KPV and rapamycin particles lowered the inflammation running alongside the calcium build-up in that 2024 model.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s28
- **c311** [mechanistic w=0.3] That 2018 work rebuilt the KPV molecule chemically, adding to it in a way meant to make it last longer before it falls apart.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s40
- **c11** [anecdotal w=0.3] A long write-up posted on Reddit walks through how KPV is thought to work, what people take it for, how they dose it and where the research stands. It is one person summarising what they have read, with no data of their own.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s9
- **c12** [anecdotal w=0.3] A YouTube video from 2025 or 2026 covers KPV for inflammation and gut trouble. The only first-hand accounts attached to it sit in the comments underneath.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s10
- **c19** [anecdotal w=0.3] People injecting KPV under the skin reported less gut pain, calmer skin rash and more energy.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s17
- **c20** [anecdotal w=0.3] A video runs through the science behind KPV, what people hope to get from it and what can go wrong. It is a summary of the literature, not a report of anyone's outcome.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s18
- **c21** [anecdotal w=0.3] In one thread, people starting KPV reported dizziness, broken sleep, headaches, brain fog and fatigue.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s19
- **c22** [anecdotal w=0.3] One person taking KPV daily said their mast cell reactions and the inflammation behind them dropped off quickly.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s20
- **c23** [anecdotal w=0.3] One person said KPV helped their gut settle once they built the dose up very slowly, after the first few doses had made things worse rather than better.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s21
- **c24** [anecdotal w=0.3] One person in a long-COVID gut thread said KPV improved how much histamine they could take in from food before reacting.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s22
- **c25** [anecdotal w=0.3] One person with mast cell activation syndrome, where the body's histamine-releasing cells fire off too easily, said KPV lifted their fatigue and widened the range of food they could eat without reacting.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s23
- **c26** [anecdotal w=0.3] Another person in that same thread put their whole symptom load at roughly 80% lower on KPV than it had been before.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s24
- **c27** [anecdotal w=0.3] One person taking a low dose of KPV reported that what it gave them was fatigue and a heavy flatness of mood, and nothing else.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s25
- **c28** [anecdotal w=0.3] A comment under a YouTube video says KPV, alongside several other things the person changed at the same time, cleared up symptoms they put down to IBS, Crohn's disease and celiac disease. With that many changes at once, nothing in the account separates KPV from the rest.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s26
- **c29** [anecdotal w=0.3] One person reported that KPV calmed their inflammation generally and improved both their skin and their gut.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s27

## Voxel graph (133 atoms · 278 edges)
- full graph: https://miscsubjects.com/api/articles/kpv/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (40 of 133)
- chain valid: yes · head: `1a565e81b4fa3513`

### s1 · pubmed · ok
- title: PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation
- url: https://pubmed.ncbi.nlm.nih.gov/18061177/
- summary: Human cell line and mouse colitis study on PepT1-mediated uptake and NF-kB inhibition
- quote: KPV acts via PepT1 expressed in immune and intestinal epithelial cells... Nanomolar concentrations of KPV inhibit the activation of NF-κB and MAP kinase inflammatory signaling pathways
- claim_ids: c1
- hash: `eb658c416c371845`

### s2 · pubmed · ok
- title: Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease
- url: https://pubmed.ncbi.nlm.nih.gov/18092346/
- summary: Mouse colitis model results
- quote: The melanocortin-derived tripeptide KPV showed significant anti-inflammatory effects in 2 murine models of colitis
- claim_ids: c2
- hash: `9e0f87fa6cc74caa`

### s3 · pubmed · ok
- title: PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation
- url: https://pubmed.ncbi.nlm.nih.gov/18061177/
- summary: Confirms mouse model efficacy
- quote: oral administration of KPV reduces the incidence of DSS- and TNBS-induced colitis
- claim_ids: c2
- hash: `a61cc5b5631aaad7`

### s4 · other · ok
- title: KPV: The Anti-Inflammatory Tripeptide for Gut and Skin
- url: https://meto.co/blog/kpv-peptide-anti-inflammatory-gut
- summary: Confirms absence of human trials
- quote: No human clinical trials exist yet... As of 2026, no registered Phase I or Phase II trials for KPV in humans are listed on ClinicalTrials.gov
- claim_ids: c3, c84
- hash: `74ae3566df0b9a01`

### s5 · other · ok
- title: KPV Research & Evidence
- url: https://peptidetreatments.com/peptides/kpv/research
- summary: Reinforces no human data
- quote: KPV has zero human clinical trials. All proposed benefits for IBD, gut health... are extrapolated from cell culture and mouse studies
- claim_ids: c3, c84
- hash: `60a1a146d6450d37`

### s6 · pubmed · ok
- title: Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin
- url: https://pubmed.ncbi.nlm.nih.gov/28343991/
- summary: 2017 study on transdermal delivery of KPV for potential skin inflammation treatment.
- quote: Lysine-proline-valine (KPV) is a C-terminal peptide fragment of α-melanocyte stimulating hormone with potent anti-inflammatory properties.
- claim_ids: c8
- hash: `c629aef257267c2d`

### s7 · review · ok
- title: KPV Peptide | Benefits, Safety & Buying Advice [2026]
- url: https://www.innerbody.com/kpv-peptide
- summary: 2026 comprehensive review summarizing KPV mechanisms, benefits for inflammation/gut/wound healing, safety concerns, and lack of human trials.
- quote: Of note, the research on KPV’s effects has been done primarily in animal models and human cell cultures, not in human subjects directly. Therefore, the support for its therapeutic uses is limited, albeit largely optimistic.
- claim_ids: c9
- hash: `b4d7eba729eea71d`

### s8 · review · ok
- title: Inflammation-triggered self-immolative conjugates enable oral delivery of anti-inflammatory peptides
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC12802832/
- summary: 2026 paper on new oral delivery system for KPV and other peptides in inflammatory conditions.
- quote: Using three anti-inflammatory peptides (KPV, Ac-QAW, and IRW), we demonstrated that the engineered conjugates exhibit remarkable GI stability
- claim_ids: c10
- hash: `6d62216c3523e827`

### s9 · reddit · ok
- title: A Complete Guide for KPV
- url: https://www.reddit.com/r/Ameano_Peptides/comments/1o7vx9t/a_complete_guide_for_kpv/
- summary: Detailed user/research guide post on Reddit explaining KPV mechanisms, benefits, dosing, and research status (anecdotal/community info).
- quote: KPV (Lysine-Proline-Valine) is a small tripeptide derived from the C-terminal sequence of α-MSH (alpha-melanocyte stimulating hormone). It is known for its potent anti-inflammatory, immunomodulatory, and mucosal healing actions, particularly in gastrointestinal and epithelial tissues.
- claim_ids: c11, c3
- hash: `8350296af4fa168c`

### s10 · youtube · http_429
- title: The Best Peptide for Inflammation, Gut Health, and Visceral Fat Loss (KPV Peptide)
- url: https://www.youtube.com/watch?v=wdCjXXmRoEw
- summary: 2025/2026 YouTube video discussing KPV benefits for inflammation and gut health with user anecdotes in comments.
- quote: KPV is a 3-amino-acid peptide (Lysine-Proline-Valine) that fights inflammation where it starts—inside your cells.
- claim_ids: c12, c3
- hash: `a33483841d80f954`

### s11 · pubmed · ok
- title: Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists
- url: https://pubmed.ncbi.nlm.nih.gov/22837805/
- summary: 2012 study on KPV's anti-inflammatory mechanism in bronchial epithelial cells via MC3R.
- quote: This study investigates the mechanism by which the α-melanocyte stimulating hormone-derived tripeptide, KPV, and the agonist of the dominant melanocortin receptor in airway epithelium (MC3R), γ-melanocyte stimulating hormone (γ-MSH), suppress inflammation in immortalised human bronchial airway epithelium.
- claim_ids: c13
- hash: `98761ae7e1ae7073`

### s12 · pubmed · ok
- title: Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model
- url: https://pubmed.ncbi.nlm.nih.gov/27458604/
- summary: 2016 mouse study showing KPV via PepT1 prevents colitis-associated cancer.
- quote: The use of an anti-inflammatory tripeptide KPV (Lys-Pro-Val) transported by PepT1 was able to prevent carcinogenesis in WT mice.
- claim_ids: c14
- hash: `7a8847b7f8a3b349`

### s13 · pubmed · ok
- title: Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis
- url: https://pubmed.ncbi.nlm.nih.gov/28143741/
- summary: 2017 study on HA-functionalized nanoparticles for targeted KPV delivery in UC mouse model.
- quote: We found that HA-KPV-NPs exert combined effects against UC by both accelerating mucosal healing and alleviating inflammation.
- claim_ids: c15
- hash: `4f9fa03739dfded0`

### s14 · review · ok
- title: KPV tripeptide
- url: https://en.wikipedia.org/wiki/KPV_tripeptide
- summary: Wikipedia entry summarizing KPV as α-MSH fragment with anti-inflammatory properties and skincare use.
- quote: KPV tripeptide (Lys-Pro-Val) is a tripeptide derivative that is derived from the C-terminal fragment of alpha-MSH. It has antiinflammatory effects, and is used in skincare products, as well as having been researched for other potential medical applications.
- claim_ids: c16
- hash: `dafafa3f157cd41b`

### s15 · medical · http_403
- title: KPV Peptide: Benefits, Dosage & 2026 Legal Status
- url: https://riteaid.com/peptides/kpv
- summary: 2026 article on KPV benefits, dosage, and updated FDA compounding legal status.
- quote: It is one of the twelve peptides the FDA removed from the list that restricted compounding in April 2026, and one of seven under formal advisory review on July 23–24, 2026.
- claim_ids: c17
- hash: `bf8e2b14f2d0910f`

### s16 · medical · ok
- title: KPV Peptide: Comprehensive Guide to Benefits, Dosage and ...
- url: https://www.helimeds.com/blog/kpv-peptide
- summary: 2026 guide covering KPV chemistry, uses, and 2026 FDA review details.
- quote: The FDAs Pharmacy Compounding Advisory Committee (PCAC) will review seven peptides to potentially allow compounders to produce them.
- claim_ids: c18
- hash: `10980839b7cefef3`

### s17 · reddit · ok
- title: Anyone here with experience using KPV or other peptides ...
- url: https://www.reddit.com/r/Biohackers/comments/1q83047/anyone_here_with_experience_using_kpv_or_other/
- summary: User anecdotes on KPV subQ use for gut pain, dermatitis, energy; benefits reversed after stopping.
- quote: I personally tried KPV subcutaneously. 200µg for 12 days (one 5mg vial). ... Significant improvements on the Bistrol scale. I no longer suffered from nighttime duodenal pain. My seborrheic dermatitis is greatly improving. More energy. No side effects.
- claim_ids: c19
- hash: `2b7b3fd6ea51fa66`

### s18 · youtube · http_429
- title: KPV Peptide - Miracle Cure or Major Risk?
- url: https://www.youtube.com/watch?v=5ph3S8mVuuE
- summary: Video discussing KPV science, benefits, and risks.
- quote: Discover the science behind KPV peptide, a powerful tripeptide known for its anti-inflammatory and immune-balancing properties.
- claim_ids: c20
- hash: `2a2f3b4466d1be1a`

### s19 · reddit · ok
- title: KPV Peptide Side Effects
- url: https://www.reddit.com/r/Longcovidgutdysbiosis/comments/1je6riv/kpv_peptide_side_effects/
- summary: User reports negative side effects from KPV including dizziness, sleep issues, headaches, brain fog, fatigue; others note it helped with MCAS inflammation or gut issues but some had to stop due to bad effects; mixed experiences with herx/die-off reactions.
- quote: Kpv & BPC157 both made me feel dizzy, impaired my sleep, gave me headaches and brain fog, and caused fatigue. It sucked bc I actually noticed ...
- claim_ids: c21
- hash: `badfcc90cf4ace5a`

### s20 · reddit · ok
- title: KPV Peptide Side Effects
- url: https://www.reddit.com/r/Longcovidgutdysbiosis/comments/1je6riv/kpv_peptide_side_effects/
- summary: Positive user experience reducing MCAS inflammation and reactions quickly with daily KPV.
- quote: Kvp simmers down the inflammation in MCAS.. almost instantly. 40 days in. 500 MCG daily. ... What I’ve noticed is since taking some peptides it’s taken the edge off and reduce the intensity of the instant reaction. Even that I’m deeply grateful for.
- claim_ids: c22
- hash: `81904e5e8e060700`

### s21 · reddit · ok
- title: KPV peptides
- url: https://www.reddit.com/r/Longcovidgutdysbiosis/comments/1iikbxd/kpv_peptides/
- summary: User reports KPV helped gut repair after slow titration despite initial paradoxical reactions; emphasizes starting low and slow.
- quote: It definitely helped with gut repair but it took me a long time to titrate up my dose. It did cause paradoxical reactions early on. After months, I'm just now at 1 capsule every other day.
- claim_ids: c23
- hash: `44ffe3f087177783`

### s22 · reddit · ok
- title: KPV peptides
- url: https://www.reddit.com/r/Longcovidgutdysbiosis/comments/1iikbxd/kpv_peptides/
- summary: Positive report of KPV improving histamine tolerance, with note on possible herx reaction at start.
- quote: Start at a very low dose, you might herx. This has helped me a lot with my histamine tolerance.
- claim_ids: c24
- hash: `347d8111ad213ca6`

### s23 · reddit · ok
- title: Is anyone being helped by peptides?
- url: https://www.reddit.com/r/MCAS/comments/1rpepqr/is_anyone_being_helped_by_peptides/
- summary: Strong positive experience with KPV reducing fatigue and improving food tolerance in MCAS context.
- quote: KPV & GHK-Cu (injections) have helped me immensely, both in terms of fatigue and in terms of food tolerance and related symptoms.
- claim_ids: c25
- hash: `505f6decbbbfaacf`

### s24 · reddit · ok
- title: Is anyone being helped by peptides?
- url: https://www.reddit.com/r/MCAS/comments/1rpepqr/is_anyone_being_helped_by_peptides/
- summary: User reports dramatic ~80% symptom reduction from KPV.
- quote: KPV has helped me dramatically. About 80% reduction in symptoms.
- claim_ids: c26
- hash: `03c572f9b6c8acb8`

### s25 · reddit · ok
- title: KPV fatigue and apathy
- url: https://www.reddit.com/r/Biohackers/comments/1ribbuz/kpv_fatigue_and_apathy/
- summary: Negative side effects reported: fatigue and strong apathy from low-dose KPV.
- quote: Been on 200mcg of KPV for a few days and am a little fatigue but the apathy seems a bit strong.
- claim_ids: c27
- hash: `216fd11f233e48d3`

### s26 · youtube · http_429
- title: This Peptide “Fixes” Your Gut... But There's a Catch
- url: https://www.youtube.com/watch?v=spOpffLj9Oo
- summary: YouTube comment sharing positive outcome: KPV (with other interventions) resolved IBS, Crohn's, celiac symptoms dramatically.
- quote: I have IBS, Crohn's and celiac. Carnivore, KPV and R e t a had helped me so much . I have my life back.
- claim_ids: c28
- hash: `8a7a4558259eda90`

### s27 · reddit · ok
- title: How effective is KPV peptide? Is it really worth it?
- url: https://www.reddit.com/r/Biohackers/comments/1s69j21/how_effective_is_kpv_peptide_is_it_really_worth_it/
- summary: Positive anecdotal report of KPV improving inflammation, skin, gut, and fungal issues like nail fungus and dandruff.
- quote: Great for overall inflammation, skin inflammation and gut health , fungus , etc. My toe nail never gets yellow anymore, dandruff completely gone ...
- claim_ids: c29
- hash: `cbc6885c1802a062`

### s28 · pubmed · ok
- title: KPV and RAPA Self-Assembled into Carrier-Free Nanodrugs for Vascular Calcification Therapy
- url: https://pubmed.ncbi.nlm.nih.gov/39252648/
- summary: 2024 study on self-assembled KPV-RAPA nanoparticles for vascular calcification, showing anti-inflammatory effects.
- quote: Herein, an anti-inflammatory peptide (lysine-proline-valine peptides , KPV ) and the autophagy activator rapamycin (RAPA) are self-assembled to form new carrier-free spherical nanoparticles (NPs), which shows good stability and biosafety.
- claim_ids: c30
- hash: `90076a9cef0776f4`

### s29 · review · ok
- title: Bioactive peptides and proteins for tissue repair
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC11619216/
- summary: 2024 review discussing KPV in tissue repair and wound healing contexts.
- quote: The KPV peptide from the bottom layer was rapidly released within 1 − 3 d to exert an anti-inflammatory effect during the early stages of wound healing, while ...
- claim_ids: c31
- hash: `4a659e8395711061`

### s30 · medical · ok
- title: Is KPV Peptide Safe To Take?
- url: https://formationmed.com/is-kpv-peptide-safe-to-take/
- summary: 2026 medical overview on KPV safety, benefits for inflammation, gut, skin; emphasizes supervision.
- quote: KPV peptide can be safe to take when it is prescribed by a licensed medical provider and sourced from a licensed compounding pharmacy that ...
- claim_ids: c32
- hash: `a7a3d4fda1d07b82`

### s31 · medical · ok
- title: KPV Peptide: Anti-Inflammatory Mechanisms and Research
- url: https://newtropin.com/peptides/kpv
- summary: 2026 clinical overview of KPV mechanisms, origin from alpha-MSH, limited human data.
- quote: Research has identified receptor expression in intestinal, dermal, and central nervous system tissues, though the pharmacokinetic profile of KPV in humans remains to be fully characterized through clinical trials.
- claim_ids: c3
- hash: `959448730a5efcc2`

### s32 · reddit · ok
- title: Best peptides and brands for MCAS ? BPC-157, KPV and ...
- url: https://www.reddit.com/r/MCAS/comments/1lki5p2/best_peptides_and_brands_for_mcas_bpc157_kpv_and/
- summary: 2026 Reddit anecdotes on KPV for MCAS, mixed experiences including improvements and side effects like flushing.
- quote: I have been using KPV Ultra and BPC-157 since April and no longer need to eat a low histamine diet.
- claim_ids: c34
- hash: `610a84254a3a81e9`

### s33 · reddit · ok
- title: KPV Explained Simply (The Gut Inflammation Fighter)
- url: https://www.reddit.com/r/PeptideProgress/comments/1u17ht6/kpv_explained_simply_the_gut_inflammation_fighter/
- summary: Recent Reddit post summarizing KPV use for gut inflammation, dosing, side effects.
- quote: KPV is a specialized peptide for a specific problem: inflammation. If you have a clear inflammatory issue, especially gut or skin related ...
- claim_ids: c35
- hash: `7e796b2d7b7540da`

### s34 · other · ok
- title: What is KPV and why is it being studied?
- url: https://www.instagram.com/reel/DYfvjzVDjSD/
- summary: 2026 Instagram reel on KPV benefits for gut and inflammation.
- quote: Benefits of KPV peptide therapy may include: • Support for gut barrier integrity • Reduced gastrointestinal inflammation • Improved digestive ...
- claim_ids: c3
- hash: `154044478c4a236d`

### s35 · review · ok
- title: Anti‐Inflammatory Peptides as Promising Therapeutics for Inflammatory Bowel Disease
- url: https://onlinelibrary.wiley.com/doi/full/10.1002/jgh3.70212
- summary: 2025 review discussing KPV/K(D)PT in IBD, including references to clinical trials and anti-inflammatory potential.
- quote: The study conducted by Kucharzik and colleagues was a phase 2 clinical trial designed to investigate the efficacy of K(D)PT medication in UC cases.
- claim_ids: c3
- hash: `956cffc62c4d47fa`

### s36 · reddit · ok
- title: KPV peptide guide
- url: https://www.reddit.com/r/NTNPerformance/comments/1talx2b/kpv_peptide_guide/
- summary: User guide on Reddit explaining KPV mechanism for gut and inflammation.
- quote: KPV is a naturally occurring tripeptide. Three amino acids. Lysine, proline, valine. It's the C-terminal fragment of alpha-MSH which is a hormone your body already produces
- claim_ids: c38
- hash: `a492a7658f6b03e3`

### s37 · youtube · http_429
- title: KPV: The Barrier Repair Peptide (Gut, Skin & Chronic Inflammation)
- url: https://www.youtube.com/watch?v=XE0k4AW0uag
- summary: YouTube video discussing KPV science, benefits for gut/skin/inflammation with anecdotal mentions.
- quote: KPV is one of the smallest peptides studied in inflammation biology — but it may be one of the most important when it comes to gut health, skin barrier repair, immune balance, and chronic inflammation, especially in midlife.
- claim_ids: c39
- hash: `026d2f039b3e7caf`

### s38 · medical · ok
- title: KPV: The Anti-Inflammatory Peptide Under FDA Review
- url: https://healingmaps.com/kpv-peptide-anti-inflammatory-wound-healing/
- summary: Article on KPV regulatory status in 2026 and preclinical evidence for inflammation/wound healing.
- quote: Regulatory Update (April 2026): KPV is one of seven peptides scheduled for FDA Pharmacy Compounding Advisory Committee review on July 23, 2026.
- claim_ids: c3
- hash: `311e4958f51006b5`

### s39 · medical · ok
- title: KPV — Molecular Specifications & Research Monograph
- url: https://peptidebiologix.com/kpv
- summary: Monograph summarizing research, including pilot clinical trial data on KPV for UC.
- quote: The most significant clinical data comes from studies in inflammatory bowel disease patients. A pilot clinical trial investigated topical (intrarectal) administration of KPV in patients with mild to moderate ulcerative colitis.
- claim_ids: c3
- hash: `3f4baf027396e7ce`

### s40 · pubmed · ok
- title: Structural modification of the tripeptide KPV by reductive amination
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC6023233/
- summary: 2018 research on modifying KPV tripeptide for improved stability, showing parent KPV degrades quickly.
- quote: The “parent” peptide , Ac- KPV -NH2 (12c) was degraded to its three constituent amino acids within 24 hours.
- claim_ids: c42
- hash: `a63b0be083288912`

## Provenance (43 model passes)
- chain valid: yes · head: `eadaf3fb6a6e7948`

- claim · fill-slots · 2026-06-29T20:42 · hash `e56cd3862f16`
- voxel_divide · owner · 2026-07-17T02:39 · hash `58d57c68b8fe`
- bind-sibling-objects · opus-5 (claude-code) · 2026-08-04T19:43 · hash `7f09ab1abbf5`
- bind-proven-work-manifest · opus-5 (claude-code) · 2026-08-04T19:47 · hash `bdbdcd5f7fd2`
- backfill-claim-provenance · opus-5 (claude-code) · 2026-08-04T19:51 · hash `7be607e3b319`
- rebind-proven-work-manifest · opus-5 (claude-code) · 2026-08-04T19:51 · hash `f4f1033ae98c`
- rebind-proven-work-manifest · opus-5 (claude-code) · 2026-08-04T19:53 · hash `5ba6d881b625`
- rebind-proven-work-manifest · opus-5 (claude-code) · 2026-08-04T19:58 · hash `eadaf3fb6a6e`

## Question graph
- questions: 0 · evidence ingests: 1

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/kpv/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/kpv/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"kpv","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest kpv|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim kpv|tier|assertion`
- **iMessage ask:** `kpv|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `kpv`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/kpv/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/kpv/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*